Panel: Uniting Founders and Funders to Align Scientific Vision with Investment Strategy

• Bringing together academic founders and investors to explore what makes DDR programs fundable

• Examining licensing, MTA bottlenecks, and funding models across early and late-stage ventures

• Offering insights into risk assessment, strategic partnerships, and scaling innovation

Speakers:

Mads Daugaard

Co-founder, President & Chief Scientific Officer

Rakovina Therapeutics, Inc.

Graeme Smith

Chief Scientific Officer

Artios Pharma

Jon Hollick

Managing Director & Head of Research

Breakpoint Therapeutics

Martin Taylor

Principal

F-Prime Capital